Pegcetacoplan Registrational Programs Begun for C3G, ALS, and IC-MPGN
Photo by Robina Weermeijer on Unsplash

Pegcetacoplan Registrational Programs Begun for C3G, ALS, and IC-MPGN

  According to a press release, biopharmaceutical company Apellis Pharmaceuticals ("Apellis") recently launched registration programs to explore pegcetacoplan for patients with C3 glomerulopathy (C3G), amyotrophic lateral sclerosis (ALS), and immune…

Continue Reading Pegcetacoplan Registrational Programs Begun for C3G, ALS, and IC-MPGN
FDA Accepts Avacopan NDA for ANCA-Associated Vasculitis
source: pixabay.com

FDA Accepts Avacopan NDA for ANCA-Associated Vasculitis

In a recent press release, biopharmaceutical company ChemoCentryx announced FDA approval for a New Drug Application (NDA) for avacopan, a treatment for ANCA-associated vasculitis. According to the FDA, a New…

Continue Reading FDA Accepts Avacopan NDA for ANCA-Associated Vasculitis
New Drug Application Submitted for Non-Steroidal ANCA-Associated Vasculitis Treatment
source: pixabay.com

New Drug Application Submitted for Non-Steroidal ANCA-Associated Vasculitis Treatment

ChemoCentryx has just announced that they have submitted their New Drug Application to the FDA for a novel ANCA-associated vasculitis therapy. It is called avacopan and it's finally something non-steroidal.…

Continue Reading New Drug Application Submitted for Non-Steroidal ANCA-Associated Vasculitis Treatment

Paroxysmal Nocturnal Hemoglobinuria Investigative Therapy Moving to Phase 3 Trial in 2020

The EMA has just announced that Danicopan has been accepted into its PRIority MEdicines (PRIME) program. Danicopan is being developed for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood condition. PRIME…

Continue Reading Paroxysmal Nocturnal Hemoglobinuria Investigative Therapy Moving to Phase 3 Trial in 2020

Orphan Drug Designation Given for Potential New Treatment for C3 Globerulopathy

Apellis Pharmaceuticals has just announced that they have received Orphan Drug Designation from the FDA for APL-2, a C3 complement inhibitor. The company is currently investigating the drug as a…

Continue Reading Orphan Drug Designation Given for Potential New Treatment for C3 Globerulopathy
Rare Kidney Disease Treatment Gets FDA’s Orphan Drug Designation
Source: Pixabay

Rare Kidney Disease Treatment Gets FDA’s Orphan Drug Designation

Last month, the FDA has granted Achillion Pharmaceuticals orphan drug designation to ACH-4471 for the treatment of patients with C3 Glomerulopathy (C3G). According to the FDA, the Orphan Drug Designation program provides…

Continue Reading Rare Kidney Disease Treatment Gets FDA’s Orphan Drug Designation
Early Study on Drug Shows Great Success in Treating C3 Glomerulopathy
Source: Pixabay

Early Study on Drug Shows Great Success in Treating C3 Glomerulopathy

A major first step for a viable treatment option! Achillion Pharmaceuticals last week reported preliminary proof-of-concept results from its ongoing Phase 2, study of a new treatment for C3 glomerulopathy…

Continue Reading Early Study on Drug Shows Great Success in Treating C3 Glomerulopathy
Europe’s on Board with This New Treatment for C3 Glomerulopathy
https://pixabay.com/en/world-map-pill-earth-healthcare-1185076/

Europe’s on Board with This New Treatment for C3 Glomerulopathy

On May 23, 2017, a biopharmaceutical company, ChemoCentryx, Inc., made a huge announcement. Not only has the US Food and Drug Administration (FDA) granted orphan drug designation for their drug, avacopan,…

Continue Reading Europe’s on Board with This New Treatment for C3 Glomerulopathy
Close Menu